<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106936</url>
  </required_header>
  <id_info>
    <org_study_id>140070</org_study_id>
    <secondary_id>14-N-0070</secondary_id>
    <nct_id>NCT02106936</nct_id>
  </id_info>
  <brief_title>Depotentiation in People With Focal Hand Dystonia</brief_title>
  <official_title>Depotentiation in Focal Hand Dystonia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prachaya Srivanitchapoom, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Focal hand dystonia (FHD) causes muscles to contract, leading to abnormal movements or&#xD;
      postures. Musicians, writers, and athletes often get it. Researchers want to study how&#xD;
      patients with this condition learn, a process of the brain that depends on a property called&#xD;
      plasticity.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      - To study brain plasticity in people with FHD.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Right-handed adults 18 years and older with FHD.&#xD;
&#xD;
        -  Healthy, right-handed adult volunteers.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with medical history, physical exam, pregnancy test, and&#xD;
           questionnaire about their right-handedness.&#xD;
&#xD;
        -  Participants will have 2 study visits on 2 different days.&#xD;
&#xD;
        -  Participants will sit in a chair and have up to 30 Transcranial Magnetic Stimulation&#xD;
           (TMS) pulses on the left side of the head. A brief electrical current passes through a&#xD;
           wire coil on the scalp. They will hear a click and may feel a pulling on the skin or&#xD;
           muscle twitches. They may have to keep their eyes open and remain alert, tense certain&#xD;
           muscles, or perform simple finger movements.&#xD;
&#xD;
        -  Forty more pulses, with 10 seconds between, will be given on the left side of the head.&#xD;
           Some will be small, some big.&#xD;
&#xD;
        -  Researchers will measure muscle response through small electrodes taped to the right&#xD;
           hand.&#xD;
&#xD;
        -  A cloth cap will be put on the participant s head. Researchers will write on tape on the&#xD;
           cap.&#xD;
&#xD;
        -  Participants will have the r-PAS. An electrical stimulator will be placed on the nerve&#xD;
           at the right wrist. Repeated magnetic pulses will be delivered in trains or short bursts&#xD;
           together with electrical stimulation of nerve. Participants will receive up to 840&#xD;
           pulses.&#xD;
&#xD;
        -  Participants will be contacted after a few days for a follow-up check.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      To explore the proper parameters creating a long-term depression (LTD)-like effect and&#xD;
      depotentiation (DePo) by using rapid paired associative stimulation (rPAS) in focal hand&#xD;
      dystonia (FHD) patients&#xD;
&#xD;
      Sample Size and Population:&#xD;
&#xD;
      We plan to recruit 28 healthy volunteers (HVs) and 28 FHD patients from the Movement&#xD;
      Disorders and Botulinum Toxin (BoNT) clinics of HMCS.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Phase 1 deals with HVs while phase 2 deals with FHD patients. We will complete phase 1 before&#xD;
      starting phase 2. Each phase is composed of 2 experiments. In phase 1, experiments 1 and 2&#xD;
      will create the LTD-like effect and DePo in HVs and in phase 2, experiments 3 and 4 will&#xD;
      elicit the LTD-like effect and DePo in FHD patients. We will use regression analysis to show&#xD;
      that the motor evoked potential (MEP) amplitude declines after eliciting the LTD-like effect&#xD;
      and DePo.&#xD;
&#xD;
      Outcome measurements:&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      Determining the parameters for creating the LTD-like effect and DePo in HVs and FHD using&#xD;
      rPAS&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Measuring the percent change of the MEP amplitude after applying the proper stimulus&#xD;
      parameters causing an LTD-like effect and DePo in both HVs and FHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 5, 2014</start_date>
  <completion_date type="Actual">June 20, 2017</completion_date>
  <primary_completion_date type="Actual">June 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Motor evoked potential amplitude</measure>
    <time_frame>Immediate</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Focal Dystonia</condition>
  <condition>Healthy Volunteers</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Must be 18 years or older&#xD;
&#xD;
          -  Must be right-handed&#xD;
&#xD;
          -  FHD includes only writer s cramp&#xD;
&#xD;
          -  Must be able to provide consent&#xD;
&#xD;
          -  No open scalp wounds or scalp infections.&#xD;
&#xD;
          -  Agrees to not drink caffeine or alcohol for 48 hours before study session.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Has used illegal drugs within the past 6 months based on history. The intent is to&#xD;
             exclude those with drug use that may affect study results. Participants who appear to&#xD;
             be intoxicated at the time of testing will be rescheduled.&#xD;
&#xD;
          -  Has more than 7 alcoholic drinks a week in the case of a woman and 14 alcoholic drinks&#xD;
             a week in the case of a man.&#xD;
&#xD;
          -  Abnormal findings on neurologic exam (other than dystonia in patient group)&#xD;
&#xD;
          -  Has had a brain tumor, a stroke, head trauma, epilepsy or a history of seizures.&#xD;
&#xD;
          -  Has major depression or any major mental disorders (axis I disorders)&#xD;
&#xD;
          -  Has a neurologic disorder other than dystonia&#xD;
&#xD;
          -  Has had a head injury where there was a loss of consciousness for more than a few&#xD;
             seconds.&#xD;
&#xD;
          -  Has metal in the body, such as a cardiac pacemaker, brain stimulator, shrapnel,&#xD;
             surgical metal, clips in the brain, cochlear implants, or metal fragments in the eye,&#xD;
&#xD;
          -  Has known hearing loss.&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Taking any medication that acts as a central nervous system stimulant or that is known&#xD;
             to lower seizure threshold, including, imipramine, amitriptyline, doxepine,&#xD;
             nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir,&#xD;
             ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel s dust),&#xD;
             ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline, mianserin, fluoxetine,&#xD;
             fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine,&#xD;
             bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine,&#xD;
             aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin,&#xD;
             ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporin,&#xD;
             chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium,&#xD;
             anticholinergics, antihistamines, and sympathomimetics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Hallett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Centonze D, Costa C, Rossi S, Prosperetti C, Pisani A, Usiello A, Bernardi G, Mercuri NB, Calabresi P. Chronic cocaine prevents depotentiation at corticostriatal synapses. Biol Psychiatry. 2006 Sep 1;60(5):436-43. Epub 2006 Feb 14.</citation>
    <PMID>16476411</PMID>
  </reference>
  <reference>
    <citation>Di Lazzaro V, Pilato F, Dileone M, Profice P, Oliviero A, Mazzone P, Insola A, Ranieri F, Meglio M, Tonali PA, Rothwell JC. The physiological basis of the effects of intermittent theta burst stimulation of the human motor cortex. J Physiol. 2008 Aug 15;586(16):3871-9. doi: 10.1113/jphysiol.2008.152736. Epub 2008 Jun 19.</citation>
    <PMID>18566003</PMID>
  </reference>
  <reference>
    <citation>Figiel GS, Epstein C, McDonald WM, Amazon-Leece J, Figiel L, Saldivia A, Glover S. The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory depressed patients. J Neuropsychiatry Clin Neurosci. 1998 Winter;10(1):20-5.</citation>
    <PMID>9547462</PMID>
  </reference>
  <verification_date>June 20, 2017</verification_date>
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Focal Hand Dystonia</keyword>
  <keyword>Depotentiation</keyword>
  <keyword>Transcranial Magnetic Stimulation (TMS)</keyword>
  <keyword>Rapid Paired Associative Stimulation</keyword>
  <keyword>Healthy Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

